Grant S - Search Results

1

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.

Bose P, Simmons GL, Grant S. Bose P, et al. Among authors: grant s. Expert Opin Investig Drugs. 2013 Jun;22(6):723-38. doi: 10.1517/13543784.2013.789859. Epub 2013 May 6. Expert Opin Investig Drugs. 2013. PMID: 23647051 Free PMC article. Review.

2

Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.

Wang Z, Su ZZ, Fisher PB, Wang S, VanTuyle G, Grant S. Wang Z, et al. Among authors: grant s. Exp Cell Res. 1998 Oct 10;244(1):105-16. doi: 10.1006/excr.1998.4191. Exp Cell Res. 1998. PMID: 9770354 Free article.

3

Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.

Wang Z, Van Tuyle G, Conrad D, Fisher PB, Dent P, Grant S. Wang Z, et al. Among authors: grant s. Cancer Res. 1999 Mar 15;59(6):1259-67. Cancer Res. 1999. PMID: 10096557

4

Protein kinase C targeting in antineoplastic treatment strategies.

Jarvis WD, Grant S. Jarvis WD, et al. Among authors: grant s. Invest New Drugs. 1999;17(3):227-40. doi: 10.1023/a:1006328303451. Invest New Drugs. 1999. PMID: 10665476 Review.

5

Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine.

Wang Z, Wang S, Fisher PB, Dent P, Grant S. Wang Z, et al. Among authors: grant s. Differentiation. 2000 Aug;66(1):1-13. doi: 10.1046/j.1432-0436.2000.066001001.x. Differentiation. 2000. PMID: 10997587

6

The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.

Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P, Grant S. Cartee L, et al. Among authors: grant s. Cancer Res. 2001 Mar 15;61(6):2583-91. Cancer Res. 2001. PMID: 11289135

7

Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).

Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S. Rosato RR, et al. Among authors: grant s. Int J Oncol. 2001 Jul;19(1):181-91. doi: 10.3892/ijo.19.1.181. Int J Oncol. 2001. PMID: 11408941

8

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.

Decker RH, Dai Y, Grant S. Decker RH, et al. Among authors: grant s. Cell Death Differ. 2001 Jul;8(7):715-24. doi: 10.1038/sj.cdd.4400868. Cell Death Differ. 2001. PMID: 11464216

9

Overview: rational integration of agents directed at novel therapeutic targets into combination chemotherapeutic regimens.

Grant S, Dent P. Grant S, et al. Curr Opin Investig Drugs. 2001 Nov;2(11):1600-5. Curr Opin Investig Drugs. 2001. PMID: 11763164 Review.

10

Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53.

Qiao L, McKinstry R, Gupta S, Gilfor D, Windle JJ, Hylemon PB, Grant S, Fisher PB, Dent P. Qiao L, et al. Among authors: grant s. Hepatology. 2002 Jul;36(1):39-48. doi: 10.1053/jhep.2002.33899. Hepatology. 2002. PMID: 12085347

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,844 results

Search Page

Filters